Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Breast Neoplasms 103Lymphoma 68Lymphoma, Large B-Cell, Diffuse 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Sarcoma 33Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Leukemia 23Burkitt Lymphoma 22Neoplasms 19Lymphoma, Mantle-Cell 18Triple Negative Breast Neoplasms 15Multiple Myeloma 15Lymphoma, Follicular 15Lymphoma, B-Cell 14Lymphoma, Large-Cell, Anaplastic 12Carcinoma, Hepatocellular 12Breast Neoplasms, Male 11Neuroblastoma 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Inflammatory Breast Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Peripheral 8Lymphoma, T-Cell 8Osteosarcoma 7Fallopian Tube Neoplasms 7Urinary Bladder Neoplasms 6Liposarcoma 6

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bladder Adenocarcinoma × Doxorubicin × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡